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Introduction: Neuropathy is one of the most frequent complications of diabetes. Of all the 
symptoms associated with diabetic neuropathy, pain has the largest impact on sleep and quality 
of life. In the past few years further medications have been added to the available therapies for 
neuropathic pain. One of these medications, duloxetine hydrochloride (duloxetine), is a balanced 
and potent selective serotonin and norepinephrine reuptake inhibitor.
Methods: Medline was searched from January 2005 to September 2009 using the key words 
duloxetine and peripheral neuropathy for clinical trials limited to human research published in 
English and duloxetine and pharmacology in the nervous system.
Results: Duloxetine has been shown to effectively reduce diabetic peripheral neuropathic pain 
compared to placebo at doses of 60 mg/day and 120 mg/day with minimal to moderate side 
effects. This effect is seen with minimal effects on glycemic control and without any clinically 
relevant effects on lipid control, or cardiovascular parameters. In addition, its efficacy and toler-
ability is comparable to other medications commonly used in the management of neuropathic 
pain. Furthermore, duloxetine performs favorably both in terms of quality of life and in cost 
utility analyses.
Discussion and conclusion: This article reviewed the issues related to management of diabetic 
peripheral neuropathic pain, the pharmacology and rationale for use of duloxetine, efficacy 
studies, and the safety and tolerability of treatment with duloxetine. Duloxetine is an acceptable 
initial or alternative treatment for patients with diabetic neuropathic pain.
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Frequency of diabetic neuropathy
The prevalence of diabetes mellitus in people age 20 years or greater in the United 
States has been estimated at 12.9%. Furthermore, the prevalence of impaired fasting 
glucose is 25.7% and of impaired glucose tolerance is 13.8%. This means that over 
40% of individuals aged 20 years or older have either diabetes or pre-diabetes, and the 
prevalence is rising.1 Peripheral neuropathy is one of the commonest complications 
of diabetes.2 At least 1 in 4 patients with diabetes is affected by a distal symmetric 
peripheral neuropathy and neuropathic pain occurs in 7.5% to 24% of all patients 
with diabetes.2,3 The yearly incidence of distal symmetric polyneuropathy in diabetics 
is approximately 2% and the lifetime incidence of neuropathy has been estimated to 
be 37% to 45% for patients with type 2 diabetes and 54% to 59% for patients with 
type 1 diabetes.2,3 The growing prevalence of type 2 diabetes mellitus in the US and 
throughout the world will result in a larger number of individuals suffering from 
diabetic peripheral neuropathic pain.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 
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Clinical features of neuropathy 
and neuropathic pain
Diabetic peripheral neuropathy may present as a large fiber, 
small fiber, autonomic neuropathy, or in varying combina-
tions of these. The neuropathy may result in pain, a dead 
numb feeling, prickling, or other positive or negative symp-
toms. The signs of diabetic neuropathy are variable but in 
diabetic symmetrical polyneuropathy (the most common 
type) include distal sensory loss affecting large or small 
fibers or both, and reduced reflexes.
Symptoms of diabetic neuropathic pain include deep, 
aching pain with superimposed burning and stabbing pain, 
allodynia, and hyperalgesia.3 Pain is often the complaint that 
motivates patients to seek medical care. However the symp-
toms of diabetic peripheral neuropathic pain are often difficult 
to treat and surveys have found that between 25% and 39% of 
patients may lack adequate treatment for their pain.3 This is a 
concern because neuropathic pain can have a major, negative 
impact on quality of life. For example, diabetic peripheral 
neuropathic pain has been reported to interfere with general 
activity, mood, mobility, work, social relations, sleep, leisure 
activities, walking ability, and enjoyment of life.2–4
Diabetic peripheral neuropathic pain is commonly attrib-
uted to a distal symmetric polyneuropathy which is associated 
with poor glycemic control.3 In painful diabetic neuropathy, 
small fibers, eg, unmyelinated (C) fibers and thinly myelinated 
(Aδ) fibers are typically affected. Prolonged stimulation of 
nociceptive afferents in the peripheral nervous system has been 
implicated in the initiation and maintenance of neuroplastic 
changes within the central nervous system. These changes result 
in persistent pain that is in part due to altered sensitivity within 
both the ascending and descending pain pathways between the 
brain and spinal cord.5 Multiple neurotransmitters are involved 
in these pain pathways. Dysfunction in these endogenous pain-
modulating circuits, which occurs in pathological pain states 
such as neuropathic pain, likely contributes to a state of central 
neuronal hyperexcitability/central sensitization. In particular, 
the neurotransmitters 5-hydroxytryptamine (serotonin) and 
norepinephrine (NE) are thought to be mediators of endogenous 
inhibitory pain mechanisms in the descending pain pathways.5,6 
Reduced inhibition of nociceptive neurons by 5-HT and NE 
in both spinal and supraspinal structures likely leads to central 
sensitization, which can produce spontaneous and persistent 
neuropathic pain.5
Approach to therapy
Currently, there are no accepted treatments to restore function 
to damaged nerve fibers. It has been shown that tight glycemic 
control can effectively slow the progression of diabetic 
neuropathy and delay the onset of neuropathy in type 1 
diabetes,7 but this is often difficult to attain.3,8 Research trials 
also show that improved glycemic control in type 2 diabetic 
polyneuropathy is associated with a lower rate of progression 
to neuropathy or in prediabetes with partial reversal of the 
neuropathy.9,10 Therefore, the current goal of treatment for dia-
betic peripheral neuropathic pain is symptomatic pain control. 
Widely used pharmacological treatments for neuropathic pain 
control include antidepressants, anticonvulsants and narcotic 
pain medications. Tricyclic antidepressants (TCAs) have been 
proposed as a first line treatment for neuropathic pain and are 
recommended as a drug of choice for treating diabetic periph-
eral neuropathic pain by the British National Formulary.11,12 
Their mechanism of action is thought to be due to NE and/or 
serotonin reuptake inhibition within the central nervous system. 
However they also have other possible mechanisms of action 
including alpha-adrenergic blockade, sodium channel effects, 
and NMDA receptor antagonism.5 Clinical use of these 
medications is often limited by side effects such as sedation, 
hypotension, dry mouth, and cardiovascular abnormalities.8 
Therefore, selective efficacious medications with fewer side 
effects would be clinically useful in the treatment of diabetic 
peripheral neuropathic pain.
Methods
A MEDLINE search (January 2005 to September 2009) was 
conducted using the key words duloxetine and peripheral 
neuropathy for clinical trials limited to human research pub-
lished in English and duloxetine and pharmacology in the 
nervous system. Subsequent searches used author names or 
references from key manuscripts. Other searches included 
the Cochrane Database of Systematic Reviews, American 
College of Physicians Journal Club, International Pharma-
ceutical Abstracts, and recently published abstracts from 
the American Diabetes Association, American Academy of 
Neurology, and Peripheral Nerve Society.
Overview of pharmacology 
and rational use of duloxetine
Even though serotonin is a known mediator of pain, random-
ized trials of selective serotonin reuptake inhibitors (SSRIs) 
have demonstrated little efficacy for relief of neuropathic 
pain.13 In fact, many SSRIs are less effective than TCAs in 
the treatment of diabetic peripheral neuropathic pain.5,14 The 
side effects of SSRIs include nausea, diarrhea, constipation, 
sleep disturbance, and sexual dysfunction.13 There is evidence 
that suggests that dual serotonin and NE reuptake inhibitors Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 
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are more effective for the relief of neuropathic pain than the 
SSRIs.15 One of the first selective serotonin and NE reuptake 
inhibitors (SSNRIs), venlafaxine, has been shown to lower 
neuropathic pain intensity. However, the difficulty with using 
venlafaxine in clinical practice is that it is predominantly 
a SSRI at low doses and only has dual SNRI properties at 
higher doses, which are often required for pain relief but are 
accompanied by side effects such as insomnia, irritability, 
dizziness, and cardiac palpitations.5,15,16
Duloxetine hydrochloride (duloxetine) and pregabalin 
are currently approved by the Food and Drug Administration 
(FDA) for the management of diabetic peripheral neuropathic 
pain. In addition, duloxetine is also used for the treatment 
of major depressive disorder (MDD), generalized anxiety 
disorder, and fibromyalgia.17–20 In addition, it is approved 
in Europe for the treatment of stress urinary incontinence.21 
Duloxetine was also found in clinical trials to significantly 
reduce the severity of painful physical symptoms that are 
associated with depression.19,20 Analysis showed that over half 
of the reduction in painful physical symptoms was due to true 
pain reduction as a direct effect from duloxetine and not a 
secondary effect due to improvement in mood.20,22 In light of 
the finding that duloxetine effectively reduced painful physical 
symptoms in MDD and evidence that serotonin and NE are 
important modulators of descending inhibitory pain pathways 
in the central nervous system, duloxetine was examined for 
pain relief in patients with neuropathic pain due to diabetic 
peripheral neuropathy without coexisting depression.20,22
Duloxetine is a potent SSNRI that has little affinity for 
other receptors or ion channels in the nervous system.5 
Animal studies have shown that duloxetine is a more potent 
inhibitor of serotonin and NE reuptake than other SNRIs, 
which include venlafaxine and milnacipran.5 It is also a 
relatively balanced dual reuptake inhibitor of both serotonin 
and NE. Animal studies in which rats were depleted of 
serotonin demonstrated that duloxetine was as efficacious 
as paroxetine, a SSRI, in blocking depletion of serotonin 
content. In addition, in rats depleted of NE, duloxetine was 
as efficacious as thionisoxetine and desipramine, which are 
selective norepinephrine reuptake inhibitors (NRIs), in block-
ing the depletion of NE concentrations.5
Animal models of acute and persistent pain demonstrated 
that duloxetine is efficacious in relieving persistent pain with-
out resulting in significant neurological deficits.23 However, 
it was found to be less efficacious in relieving acute pain.5 
This finding was explained based on the different underlying 
pathologic mechanisms behind acute and persistent pain. 
In the animal model used for acute pain, the tail-flick test, 
there is no tissue or nerve damage and the pain response 
mainly involves a spinally mediated reflex. In contrast, the 
animal models of persistent pain, the formalin model and 
L5/L6 nerve ligation, involve tissue and nerve injury. These 
injuries lead to hyperexcitabiltiy of neurons in the spinal 
cord and supraspinal pain pathways, which is referred to 
as central sensitization.5 Central sensitization is due to an 
imbalance between the endogenous inhibitory and excitatory 
pain pathways. Therefore, a medication such as duloxetine 
that blocks the reuptake of serotonin and NE, which are both 
key mediators of the descending pain pathways, should be 
effective in relieving persistent neuropathic pain.5
Duloxetine is absorbed beginning 2 hours after oral 
administration and the maximum plasma concentration is 
achieved in approximately 6 hours. Taking duloxetine with 
food increases the time to peak absorption by 6 to 10 hours, 
but it does not effect its maximum plasma concentration. 
In addition, administration in the evening compared to the 
morning results in a 3-hour delay in the absorption and 
increases clearance by approximately 33%.13
Duloxetine is metabolized rapidly by cytochrome P-450 
enzymes and has a half-life of approximately 12 hours. 
Over 70% of the metabolites are excreted in the urine 
and the remaining 20% are excreted in the feces. None of 
duloxetine’s metabolites have been found to contribute 
significantly to its pharmacologic activity.13 There are no 
recommendations to adjust the dose of duloxetine when it 
is given with other medications that are metabolized by the 
cytochrome P-450 enzymes. However, use of duloxetine in 
combination with a monoamine oxidase inhibitor (MAOI) 
medication is contraindicated and duloxetine should not be 
started until 14 days after discontinuing therapy with an 
MAOI. This recommendation is due to the risk of serious or 
fatal reactions reported in patients taking serotonergic medi-
cations in combination with a MAOI. These reactions include 
the serotonin syndrome, which includes the following signs: 
hyperthermia, rigidity, myoclonus, autonomic instability, 
and mental status changes that may progress to delirium 
or coma.13 The use of duloxetine is also contraindicated in 
patients with uncontrolled narrow-angle glaucoma.
Precaution should be used if duloxetine is used in patients 
with hepatic insufficiency and it should not be used in patients 
with a substantial history of alcohol use or evidence of 
chronic liver disease. In patients with hepatic dysfunction the 
mean plasma clearance is 15% of that observed in patients 
with normal liver function and the half-life increases 3-fold. 
In addition, duloxetine is not recommended in patients with 
a creatinine clearance of less than 30 mL/min.13Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 10
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Duloxetine is a highly protein-bound medication (90%). 
To date, the interactions between duloxetine and other 
highly protein-bound medications have not been evaluated. 
Therefore it is recommended that either adding or removing 
duloxetine to an existing medication regimen be done with 
caution if there is a concern for an effect on protein binding. 
In addition, duloxetine is a pregnancy category C medication 
and it is recommended that the dose may need to be tapered 
and the drug discontinued in pregnant women.13
Efficacy studies with duloxetine 
in neuropathic pain
Clinical studies have shown that duloxetine is effective and 
safe in the management of diabetic peripheral neuropathic 
pain.6,15,20 To date, there have been three randomized, double-
blind, multicenter, placebo-controlled trials to assess the 
efficacy and safety of duloxetine (Table 1). All three tri-
als were 12-week acute therapy trials. Enrollment criteria 
included the presence of a bilateral, symmetric neuropathy 
associated with either type 1 or type 2 diabetes mellitus that 
caused daily pain for at least 6 months. The mean average 
daily pain severity had to be at least 4 on an 11-point Likert 
scale (0 = no pain, 10 = worst pain possible). The primary 
efficacy endpoint in these studies was either a 30% or 50% 
reduction in a 24-hour average pain score on the Likert scale. 
This endpoint was chosen because previous studies involv-
ing patients with chronic pain syndromes have shown that 
an average reduction of 2 or more points, or approximately 
30% from baseline on an 11-point pain rating scale correlates 
with a clinically meaningful improvement as determined by 
the 7-point patient global impression of change. In fact, a 
30% change in the pain intensity numerical rating scale cor-
related with a patient global impression category of “much 
improved” and a 50% change corresponded to “very much 
improved”.24
All three trials demonstrated a statistically significant 
reduction in pain severity for duloxetine 60 mg once a day 
(60 mg/day) and 60 mg twice a day (120 mg/day) compared 
to placebo. There was no significant difference in efficacy 
seen between these two treatment groups.6,15,20 The study by 
Goldstein et al included a duloxetine 20 mg once-a-day treat-
ment group, and found that this group had a nonsignificant 
decrease in pain severity compared to placebo.20
The significant reduction in pain for the duloxetine 
60 mg/day and 120 mg/day treatment groups was seen begin-
ning in the first week of therapy and it persisted throughout 
the length of the study.20 Even though most of the responses 
to duloxetine occurred in the first 1 to 2 weeks of treatment, 
a potential benefit to continuing therapy with duloxetine was 
observed. Specifically, of those patients that did not have a 
significant response to duloxetine after 6 weeks of therapy, 
approximately one-third achieved a significant response after 
the remaining 12 weeks of treatment.25
A pooled analysis of these three studies found that 
approximately two-thirds of patients who were treated 
with duloxetine achieved a 30% or greater reduction in 
24-hour average pain severity. Using the alternative criteria 
of a 2-point reduction on the 11-point pain rating scale, 
approximately 60% of the patients treated with duloxetine 
achieved this clinically meaningful improvement in pain 
severity. Applying the more stringent criteria of a 50% or 
greater reduction in 24-hour average pain severity, approxi-
mately half of all duloxetine-treated patients achieved a 
response compared to 28% of those receiving placebo.25 The 
response rates, defined as 50% pain reduction, were 48.2% 
(120 mg/day), 47.2% (60 mg/day), and 27.9% (placebo).3
Secondary measures of pain were also significantly 
improved in both the duloxetine 60 mg/day and 120 mg/day 
treatment groups compared to placebo.15,20 These second-
ary measures included worst pain, night pain, the Brief 
Pain Inventory (BPI) average pain severity, BPI worst pain 
severity, BPI least pain severity, BPI pain severity right now, 
and the Short-Form McGill Pain Questionnaire (SF-MPQ) 
total score.20 The patients in the duloxetine 20 mg once-a-day 
treatment group had significant improvements compared to 
placebo on measures of worst pain score and the SF-MPQ 
total score.20 In addition, further analysis revealed that there 
was a significantly higher percentage of patients taking dulox-
etine 120 mg/day who reported improvement in shooting, 
stabbing, sharp, hot-burning, and splitting pain sensations 
compared to patients in the placebo group.20
The pooled data from the three placebo-controlled studies 
of duloxetine was also examined to determine the impact of 
baseline disease variables related to diabetes and diabetic 
neuropathy severity on the efficacy of duloxetine. There 
were no significant effects of age, type of diabetes, duration 
of diabetes, duration of diabetic neuropathy, severity of dia-
betic neuropathy as measured by the Michigan Neuropathy 
Screening Instrument, or baseline hemoglobin A1C on the 
efficacy of duloxetine. However, it was found that duloxetine 
was more effective in patients with higher initial pain scores 
(BPI average pain of 6 or greater).26
Another measure of efficacy for pain relief that was 
examined in the clinical trials was the average daily dose 
of supplemental analgesic medication used. Goldstein et al 
performed a comparison that demonstrated that patients Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 11
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who were treated with duloxetine at any dose (20 mg/day, 
60 mg/day, or 120 mg/day) required a lower average daily 
dose of supplemental analgesic medication compared to 
patients who received placebo.20 The duloxetine 60 mg/day 
and 120 mg/day treatment groups used significantly less anal-
gesic medication than the placebo group and the duloxetine 
20 mg/day group used numerically less than the placebo 
group.20 In 2 other studies it was found that only patients 
treated with duloxetine 120 mg/day took significantly less 
supplemental analgesic medication than patients treated 
with either duloxetine 60 mg/day or placebo.6,15 This result 
provides evidence of additional efficacy of duloxetine 
120 mg/day compared to 60 mg/day, however there is also 
an increase in adverse effects.22
An open-label study by Skljarevski et al that enrolled 
216 patients concluded that the effect of duloxetine 60 mg/day 
in patients with diabetic peripheral neuropathic pain was 
maintained over a longer, 6-month treatment period.23 In 
addition, there was an arm in the study for patients who were 
nonresponders to therapy with duloxetine 60 mg/day. After 
8 weeks of therapy with duloxetine 60 mg/day, patients who 
did not report at least a 30% decrease in 24-hour average 
pain were then treated with duloxetine 120 mg/day for the 
remainder of the study, which was 26 weeks. This study found 
that 115 patients (53%) responded to duloxetine 60 mg/day 
and were put into the maintenance arm. The remaining par-
ticipants, the nonresponders, who received an increased dose 
of duloxetine 120 mg/day, reported a statistically significant 
reduction in their 24-hour average pain. Findings from this 
study suggest that treatment with duloxetine 120 mg/day 
provides an additional 10% of patients with a clinically sig-
nificant pain reduction of 50%.11
Data derived from a meta-analysis and original publica-
tions of duloxetine vs pregablin and gabapentin in the treat-
ment of diabetic peripheral neuropathic pain is shown in 
Table 2.11 The primary endpoints for efficacy in pain control 
were reduction in 24-hour pain severity, response rate of 50% 
or greater pain reduction, and Patient Global Impression of 
Improvement/Change (PCI-I/C). This meta-analysis concluded 
that duloxetine had comparable efficacy and tolerability to 
gabapentin and pregabalin in the treatment of diabetic peripheral 
neuropathic pain. It was determined that all three drugs were 
superior to placebo for all three efficacy measures.11
In the study by Quilici et al pooled analysis estimated 
that the number needed to treat for improvement in pain was 5 
(95% confidence interval [CI] 3 to 7) for duloxetine and 5 
(95% CI 4 to 8) for pregabalin.11 A different pooled analysis 
of 6 placebo-controlled trials of duloxetine estimated the 
number needed to treat with duloxetine as 5.9 (95% CI 4.8 
to 7.7).17 Other reviews have reported the number needed to 
treat for gabapentin as 3.4 or 3.8, but this does not represent 
a direct comparison. Furthermore, the number needed to 
treat for the TCAs has previously been estimated at approxi-
mately 3, but these trials were small crossover trials that may 
overestimate the efficacy of TCAs.11
A recent systematic review of treatments for diabetic 
peripheral neuropathic pain found that oral tricyclic anti-
depressants and traditional anticonvulsants were better for 
short-term pain relief than newer-generation anticonvulsants.8 
The classes of drugs included in this study were paracetamol 
(acetaminophen), antidepressants, opioids, nonsteroidal 
anti-inflammatory drugs, N-methyl-D-aspartate antago-
nists, tramadol, capsaicin, and anticonvulsants. All drugs 
were compared to placebo and efficacy was defined as a 
50% or greater reduction in pain. This study found that oral 
tricyclic antidepressants, anticonvulsants (sodium valproate, 
lamotrigine, carbamazepine), and opioids had better efficacy 
than newer-generation anticonvulsants (oxcarbazepine, pre-
gabalin, gabapentin), a selective serotonin reuptake inhibitor 
(citalopram), and duloxetine.8 Shortcomings of this review 
include the fact that it is difficult to compare outcomes, 
especially when related to pain, if different primary endpoints 
are used. In addition, sample sizes of the included trials were 
small, the treatment period was less then 6 months in all the 
studies, and some of the trials used a crossover design with-
out a washout period. In the studies with a crossover design 
there may have been selection bias because only data from 
the first period was used to calculate efficacy. Furthermore, 
some medications had multiple studies included in the 
analysis, some of which had contradictory results, and other 
medications may have only had 1 study included. It is clear 
that further, long-term and head-to-head studies are needed 
to examine the efficacy of commonly used pharmacological 
treatments for diabetic peripheral neuropathic pain.
Although treatment with duloxetine has a significant 
effect on diabetic peripheral neuropathic pain, it has not 
been found to alter peripheral nervous system pathology or 
result in regeneration of peripheral nerve axons. In studies 
of duloxetine there were no treatment group differences in 
any electrophysiologic measures of nerve function, includ-
ing nerve conduction studies of the ulnar and peroneal 
nerves.6,15
Safety and tolerability of duloxetine
In all of the clinical studies, the incidence of serious adverse 
events associated with treatment with duloxetine was low and Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 13
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the medication was generally well tolerated.6,15,20 Reported 
side effects, which were typically mild to moderate in 
severity, included nausea, fatigue, somnolence, increased 
sweating, dry mouth, dizziness, diarrhea, constipation, 
insomnia, decreased appetite, asthenia, erectile dysfunction, 
weakness, and tremor.6,11,15,17
In the study by Goldstein et al less than 20% of subjects 
discontinued participation in the trial because of adverse 
events. There was not a significant difference in reported 
treatment-emergent adverse events (TEAE) in the duloxetine 
20 mg/day treatment group compared to placebo. There were 
more discontinuations due to adverse events in the duloxetine 
60 mg/day and 120 mg/day treatment groups compared to 
the placebo group. However, the only TEAEs that occurred 
significantly more frequently in the duloxetine 60 mg/day 
treatment group compared to placebo were somnolence and 
constipation. Except for somnolence, which was reported 
as severe in the duloxetine 120 mg/day treatment group, 
most of the reported adverse effects were mild to moderate 
in severity.20
Other trials by Raskin et al and Wernicke et al also found 
that there was a significant increase in reported TEAEs in the 
duloxetine 60 mg/day and 120 mg/day treatment groups.6,15 
These events were also generally mild to moderate in sever-
ity. Patients in both duloxetine treatment groups reported a 
significant increase in treatment-emergent nausea, somno-
lence, hyperhydrosis and anorexia compared to placebo. 
Furthermore, patients in the duloxetine 120 mg/day treatment 
group had significantly more frequent vomiting and constipa-
tion than patients in the placebo group. Compared to placebo, 
there were significantly more patients in the duloxetine 
120 mg/day treatment group who discontinued therapy due 
to TEAEs. Adverse events that lead to discontinuation of the 
medication in at least 1% of duloxetine treated patients were 
nausea, vomiting, dizziness, somnolence, and fatigue.6,15
A longer-term study of patients with diabetic periph-
eral neuropathic pain examined the safety of duloxetine 
120 mg/day compared to routine care for up to 52 weeks.27 
It was found that there were no significant differences in the 
occurrence of serious adverse events. The one TEAE with a 
significant group difference was asthenia, which occurred at 
a higher frequency in patients treated with duloxetine.27
Pooled analysis of trials of duloxetine in diabetic periph-
eral neuropathic pain have found that treatment with dulox-
etine leads to a significantly higher incidence of dizziness, 
nausea, headache, and somnolence.11 These TEAEs typically 
occur at the beginning of drug therapy and resolved over 
time.20,28 Furthermore, most patients who discontinued dulox-
etine due to adverse events did so within the first 4 weeks of 
treatment.6 An explanation for this may be that these trials 
typically start patients on 60 mg of duloxetine once a day 
and after 3 days increased the dose to 60 mg twice a day. 
A slower titration schedule may likely decrease the incidence 
of TEAEs. In fact, studies in patients with major depressive 
disorder suggested that either starting patients on a dose of 
duloxetine 30 mg once a day for a week or starting 60 mg in 
the morning with food may reduce the incidence of nausea 
compared to a starting dose of 60 mg once a day.18
Another question on the administration of duloxetine 
in clinical practice is once daily vs twice daily dosing. 
Table 2 indirect comparison of neuropathic pain results: duloxetine vs pregabalin
Outcome Mean difference 
in treatment effects
95% confidence 
interval
Comments
Mean reduction in 
24-hour pain score
−0.248 0.667; 0.162 Duloxetine was not inferior to 
pregabalin
Patient global impression 
of change
0.542 0.016; 1.060 Pregabalin was slightly more 
effective than duloxetine
Premature discontinuation 
due to lack of efficacy
−0.251 −1.288; 0.717 No statistical difference found
Premature discontinuation 
due to adverse events
0.152 −0.505; 0.790 No statistical difference found
Diarrhea 0.886 −0.414; 2.183 No statistical difference found
Dizziness −1.084 −1.903; −0.317 Duloxetine produced a significantly 
lower incidence of dizziness
Headache 0.700 −0.078; 1.458 No statistical difference found
Somnolence −0.554 −1.458; 0.328 No statistical difference found
Note: Derived from data of.6,11,15,20,33–37Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 14
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A 28-week open label safety study of duloxetine 60 mg twice 
daily or 120 mg once daily found that both doses were safe 
and well tolerated for the duration of the trial.28 There were 
few differences in safety or tolerability between the two 
doses and both doses provided clinically significant reduc-
tion of pain. However, there were more discontinuations due 
to adverse effects in the duloxetine 120 mg once daily arm, 
which suggests that a dosing regimen of duloxetine 60 mg 
twice daily may be better tolerated.
One study found that some TEAEs, such as back pain, 
arthralgias, and pruritis, were reported significantly less 
frequently by the duloxetine 60 mg/day and 120 mg/day treat-
ment groups compared to placebo. In addition, the patients 
in the placebo group experienced a significantly greater 
incidence of lower limb edema and peripheral swelling than 
the duloxetine treated patients.20
A meta-analysis of duloxetine vs pregablin and gaba-
pentin in the treatment of diabetic peripheral neuropathic 
pain found that treatment with duloxetine, pregabalin, or 
gabapentin resulted in a significantly higher rate of discon-
tinuation due to adverse events compared to placebo. The 
most commonly reported TEAEs for both pregabalin and 
gabapentin were dizziness and somnolence and duloxetine 
treatment resulted in significantly higher reports of dizziness, 
headache, nausea, and somnolence than placebo. However, 
duloxetine produced a significantly lower incidence of diz-
ziness compared to pregabalin.11
In all of the studies of duloxetine for the treatment of dia-
betic peripheral neuropathic pain there were several serious 
adverse events reported. Serious adverse events were defined 
as any event resulting in or prolonging hospitalization or 
death, a life threatening experience, or severe or permanent 
disability. There were no significant group differences in 
the occurrence of serious adverse events between the dulox-
etine treatment groups and placebo and none of the serious 
adverse events were determined to be due to treatment with 
duloxetine.6,15,20
There have been case reports of patients developing 
hepatic failure while taking duloxetine. The incidence of this 
occurrence is approximately 1 to 2 per 100,000 exposures 
and it is more common in patients with a history of signifi-
cant alcohol use and/or chronic liver disease.29 In addition, 
a small fraction of patients treated with duloxetine have been 
found to have elevations in their liver enzymes that resolve 
spontaneously. Overall the hepatic risk of duloxetine has been 
determined to be within the range for other medications and 
does not require monitoring of hepatic enzymes.29 However, 
it is recommended that duloxetine should not be prescribed to 
patients with substantial alcohol use or evidence of chronic 
liver disease and it should be discontinued in patients who 
develop jaundice or other evidence of clinically significant 
liver dysfunction.
In addition to adverse events, there were no clinically 
meaningful changes in laboratory data including blood 
chemistry, hematology, glycemic control, or lipid levels with 
duloxetine treatment.6,15,20 Due to duloxetine’s noradrenergic 
potentiation, careful measurements of blood pressure, heart 
rate, and the QTc interval on electrocardiogram were moni-
tored. Studies of duloxetine have found that there is an average 
increase of 2 mmHg in diastolic blood pressure and an eleva-
tion in baseline heart rate of approximately 2 to 3 beats/min.30 
These findings were significant when compared to placebo but 
were not determined to be clinically significant. In addition, 
duloxetine was not found to adversely affect the QTc interval, 
which can be prolonged by medications such as TCAs,6,15,20 or 
systolic blood pressure even during a year-long safety study.27 
These findings led to the conclusion that patients with diabe-
tes who are treated with duloxetine do not require additional 
cardiovascular monitoring other than what is indicated for 
treatment of their underlying diabetes.6,15,20,28
Duloxetine and quality of life 
measures in neuropathy
The impact that treatment with duloxetine had on quality of 
life measures in patients with diabetic peripheral neuropathic 
pain were included in the clinical trials with measures of 
general illness severity and improvement as well as health 
outcome scores, which were examined as secondary mea-
sures. Overall there were significant improvements in most 
measures of quality of life in addition to pain reduction due 
to treatment with duloxetine.15,20 The duloxetine 60 mg/day 
and 120 mg/day groups had significant improvements in 
measures of general illness severity and improvement, as 
measured by the Clinical Global Impression of Severity and 
Patients Global Impression of Improvement, and the dulox-
etine 20 mg/day group had significant improvements in the 
Clinical Global Impressions of Severity.20
Health outcome measures were evaluated by use of patient 
completed questionnaires. These included the BPI-Interference, 
Euro Quality of Life instrument (EQ-5D), and the Short 
Form-36 (SF-36) Health Status Survey. The BPI-Interference 
measures how much pain interferes with several patient 
outcomes including general activity, mood, walking, ability, 
sleep, and interpersonal relationships. The EQ-5D measures 
how severe the patient perceived general health. The SF-36 
measures how a patient perceives their general status and Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 15
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consists of 36 items that calculate 8 health domains: bodily 
pain, general health, mental health, physical functioning, 
physical role, emotional role, social function, and vitality.
Pooled analysis from the three randomized, double-blind, 
multicenter, placebo-controlled trials of duloxetine in diabetic 
peripheral neuropathic pain demonstrated that patients treated 
with duloxetine improved significantly on all health outcome 
measures compared to placebo. The measures of functional 
outcomes had robust improvements that were unaffected by 
either the time or incidence of patient withdrawal.4 A study 
comparing duloxetine with routine care in patients with dia-
betic peripheral neuropathic pain found a significant group 
difference in the SF-36 physical component summary score 
and subscale scores of physical functioning, bodily pain, 
mental health, and vitality in patients who were treated with 
duloxetine 60 mg twice a day compared to those who received 
routine care.27
Previous studies have shown that patients with diabetes 
consistently score lower than age matched individuals with-
out the disease on patient-rated measures of quality of life and 
that diabetes is associated with deficits in health-related qual-
ity of life.4 The result that treatment with duloxetine results 
in improvement in health outcome measures suggests that 
treatment with duloxetine was associated with a significant 
improvement in daily functioning. This emphasizes the clini-
cal role of duloxetine in management of patients with diabetic 
peripheral neuropathic pain and its potential to significantly 
improve quality of life in these patients.
The question arises whether the improvement in measures 
of quality of life seen with duloxetine therapy is due to its 
effect as an antidepressant or due to a reduction in neuropathic 
pain. In addition, it is unclear how much pain reduction can 
be attributed to improvements in mood and what effect on 
mood duloxetine may have on patients who do not have 
MDD. For this reason, patients who met criteria within the 
past year for the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV) Axis I diagnosis of 
MDD, dysthymic disorder, generalized anxiety disorder, 
alcohol or eating disorders were excluded from enrollment in 
the duloxetine studies of efficacy in diabetic peripheral neu-
ropathic pain. To screen for subclinical depression, changes 
in mood and anxiety were measured at enrollment and at the 
end of the trials with either the Hamilton Rating Scale for 
Depression (HAMD) or the Beck Depression Inventory-II 
and the Beck Anxiety Inventory.
It was found that there were no significant changes in 
mood or anxiety between groups treated with duloxetine and 
placebo.6,15,20 In addition, the mean change in mood from 
baseline to endpoint as measured with the HAMD was very 
similar in the placebo and treatment groups.6 This finding 
was explained based on the exclusion criteria and the fact 
that baseline measures of depression and anxiety were low in 
these subjects, with little measurable room for improvement 
and it suggests that duloxetine has a neutral effect on mood for 
patients who do not have a clinical diagnosis of depression.6,15,20 
Further analysis showed that more than 90% of the reduction 
in pain was due to a direct effect on pain modulation and not 
due to an antidepressant effect of duloxetine.6,30
Conclusion: the place of duloxetine 
in the treatment of diabetic 
neuropathic pain
Duloxetine is approved by the FDA specifically for the 
treatment of diabetic peripheral neuropathic pain. It has 
been proven to be superior to placebo at doses of 60 mg/day 
and 120 mg/day in treating diabetic peripheral neuropathic 
pain and its effect of reducing 24-hour average pain is seen 
early, typically within the first week. Comparison studies 
have shown that its efficacy is comparable to that of other 
medications commonly used for the treatment of diabetic 
peripheral neuropathic pain. Duloxetine is relatively well 
tolerated. However, lower titration schedules may improve 
tolerability. Greater pain efficacy may be attained with doses 
higher than 60 mg/day in patients who do not respond to the 
recommended maintenance dose. Clinically relevant changes 
in health outcome measures that affect quality of life have 
also been found to improve with therapy.
In addition to safety and efficacy, the cost of medications 
is a major concern for patients and clinicians. A recent study 
by Beard et al examined the cost-effectiveness of duloxetine 
in the treatment of diabetic peripheral neuropathic pain in the 
UK. The standard approach to treatment of diabetic peripheral 
neuropathy in the UK is to use a TCA as a first-line trial of 
treatment. Other medications such as anticonvulsants are 
then tried before using narcotics for pain control. Given this 
paradigm, they found that the second line use of duloxetine is 
a beneficial and cost-effective treatment strategy for diabetic 
peripheral neuropathic pain.12 A similar study in the US 
examined the relative efficacy, costs, and cost effectiveness 
of first-line treatment options for painful diabetic neuropathy. 
This study found that desipramine and duloxetine were both 
more effective and less expensive than gabapentin and prega-
balin.31 In comparison with pregabalin, it was found that even 
though duloxetine and pregabalin had comparable levels of 
a full response (at least a 50% reduction in pain), treatment 
with pregabalin resulted in a greater proportion of patients Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 16
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with a partial response (30% to 49% reduction in pain). 
Prior studies have demonstrated clear differences in health 
utility between full and partial pain response that impacts the 
cost-effectiveness of alternative treatments. Patients taking 
duloxetine would be less likely to have a partial pain response 
and require additional therapy with other costly medications.12 
Therefore, duloxetine is an acceptable initial or alternative 
treatment for patients with diabetic neuropathic pain.
Unfortunately, treatment algorithms for painful diabetic 
neuropathy are based upon clinical experience and pooled 
data from trials with relatively small sample sizes, nonstan-
dardized markers of efficacy, and short follow-up studies. 
Furthermore, there is a lack of data from head-to-head 
comparison trials, which prohibits true evaluation of the 
safety and efficacy of widely used neuropathic pain agents. 
Trials are needed that use 1) head-to-head comparisons or 
individual neuropathic pain medication or combinations of 
pain medications, 2) longer durations of follow-up, and 3) use 
of standardized and validated pain assessment scales to allow 
accurate comparison of data across trials.32
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